VCEL

Vericel Corporation

Healthcare · $2.1B market cap

We can't put a fair value on VCEL right now. It has fewer than 5 profitable years and uneven cash flow, not enough history to project from yet.

Business quality

2 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth42.7% a year✓

Equity per share growth-5.4% a year✗

Sales growth20.1% a year✓

Free cash flow growth-7.5% a year✗

Return on invested capital0.5%✗

Follow VCEL

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds VCEL. Who we track

Mairs & Power Funds

Mairs & Power Funds · as of Q2 2026

$1.2M

25,865 shares

About Vericel Corporation

Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works

Verdict

Business quality

Superinvestors

About Vericel Corporation